Ernesto Korbenfeld
Hospital Británico(UY)Hospital Británico de Buenos Aires(AR)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies
Most-Cited Works
- → Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial(2014)1,480 cited
- → Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial(2015)1,174 cited
- → Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC(2024)331 cited
- → Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer(2023)299 cited
- → Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors(2020)170 cited
- → Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01(2024)110 cited
- → Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study(2024)98 cited
- → Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial(2023)83 cited
- → LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial(2023)83 cited
- → Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study(2021)67 cited